ライフサイエンスコーパス: dysphoria

1 -related and addictive disorders, and gender dysphoria).

2 More than 1 in 4 patients had moderate dysphoria.

3 rapeutic options for women with premenstrual dysphoria.

4 development and their relationship to gender dysphoria.

5 l: n = 7328 [29%]) had a diagnosis of gender dysphoria.

6 xploring how they could contribute to gender dysphoria.

7 poor understanding of the etiology of gender dysphoria.

8 iverse (TGGD) patients who experience gender dysphoria.

9 rstanding the underlying mechanism of gender dysphoria.

10 Top surgery may be performed to treat chest dysphoria.

11 ren and may be prodromal markers of risk for dysphoria.

12 ing the sensitivity to stressful stimuli and dysphoria.

13 this treatment for youth experiencing gender dysphoria.

14 ased signaling may produce analgesia without dysphoria.

15 depressive-like states such as anhedonia and dysphoria.

16 rbance and co-occurring anxiety disorders or dysphoria.

17 se without a history of anxiety disorders or dysphoria.

18 high rates of anxiety disorders and chronic dysphoria.

19 d is consistent with a link between CREB and dysphoria.

20 2 because of vernacular changes referring to dysphoria.

21 s anhedonia, craving, fatigue, insomnia, and dysphoria.

22 ve pictures showed the greatest increases in dysphoria 2 years later.

23 A history of major depressive episode, dysphoria (2 weeks of sadness), and psychotropic medicat

24 ects of diagnosis and treatment condition on dysphoria after quitting smoking and the effects of dysp

25 Gender dysphoria alone was associated with a lower mean (SD) CH

26 Dysphoria alone was not reliably related to pain reports

27 y (GAS) is an effective treatment for gender dysphoria among transgender, nonbinary, and gender diver

28 These data suggest that a history of dysphoria and a major depressive episode increase the ri

29 be improved by using multiple questions for dysphoria and a simpler mode of inquiry.

30 ble about the diagnostic criteria for gender dysphoria and criteria for gender-affirming treatment, h

31 g hormone therapy and improvements in gender dysphoria and depression, but there is a lack of data fr

32 ut their clinical application was limited by dysphoria and hallucinations.

33 for transgender individuals to reduce gender dysphoria and improve quality of life.

34 s and is associated with reduced symptoms of dysphoria and improved quality of life.

35 profile suggests that it will be without the dysphoria and other adverse effects promoted by arrestin

36 pression in patients with CVD improves their dysphoria and other signs and symptoms of depression, im

37 ole of ovarian steroids in both premenstrual dysphoria and perimenopausal depression has led to the s

38 ors (KOR) in serotonergic neurons to produce dysphoria and potentiate drug reward; however, the circu

39 uch as leuprolide, can help alleviate gender dysphoria and provide additional time before irreversibl

40 he case of kappa-opioid receptor (kappa-OR)--dysphoria and psychotomimesis.

41 rs an approach to controlling stress-induced dysphoria and relapse.

42 0488, a kappa-opioid agonist known to induce dysphoria and stress-like effects in rodents.

43 or without surgery, to improve their gender dysphoria and to better align their physical and psychol

44 ) and psilocybin for depression, end of life dysphoria, and alcohol use disorder.

45 rs such as heightened anxiety, irritability, dysphoria, and anhedonia, which pose a significant risk

46 d, implicates dynorphin as a key mediator of dysphoria, and emphasizes kappa-receptor antagonists as

47 ed by some KOR agonists, including sedation, dysphoria, and hallucinations, have limited their clinic

48 er scores for items related to anger, worry, dysphoria, and irritability.

49 characteristics (eg, gender identity, gender dysphoria, and mental health difficulties).

50 sures of specific depressive symptoms (i.e., dysphoria, anhedonia, somatic concerns, negative cogniti

51 icolimbic system; the ensuing kappa-mediated dysphoria appears to contribute to addiction and withdra

52 experience reward (anhedonia) and aversion (dysphoria) are in high demand because many psychiatric c

53 r than placebo for treatment of premenstrual dysphoria as reflected by symptomatic improvement and ch

54 The primary outcome was gender dysphoria, as measured by the Gender Preoccupation and S

55 Interestingly, KOR-mediated dysphoria, assessed in rodents as aversion, has recently

56 Dysphoria associated with KOR activation limits the ther

57 ain the rapid alleviation of the anxiety and dysphoria associated with late luteal phase dysphoria di

58 ld contribute to alleviating the anxiety and dysphoria associated with the symptomatology of major un

59 Here, we identify the stress- and dysphoria-associated kappa opioid receptor (KOR) and its

60 ral to their detrimental side effects (e.g., dysphoria/aversion).

61 e identified: apathy without moderate-severe dysphoria, behavioural disinhibition, irritability/agita

62 with analgesia being G protein-mediated and dysphoria being mediated through betaarrestin2 recruitme

63 7 months after imaging controlling for prior dysphoria (beta = -.11, p = .004).

64 spouses, who received a diagnosis of gender dysphoria between September 1, 2016, and December 31, 20

65 d adolescents may experience not only gender dysphoria but also depression and anxiety, all of which

66 ot with dysphoria; pattern 2 correlated with dysphoria but not with the cognitive measures.

67 e suggested a genetic contribution to gender dysphoria, but previously proposed candidate genes have

68 eceptor system modulates negative affect and dysphoria, but recent studies now implicate the kappa op

69 sgender (TG) adolescents to alleviate gender dysphoria, but the effect of GAHT on the growing skeleto

70 th no treatment significantly reduced gender dysphoria, depression, and suicidality in transgender an

71 tinue the study, and have increased rates of dysphoria, depressive symptoms, and extrapyramidal sympt

72 Gender dysphoria describes the psychological distress caused by

73 dysphoria associated with late luteal phase dysphoria disorder and major unipolar depression by thes

74 sts produce other adverse effects, including dysphoria, diuresis, and constipation.

75 Transgender women experience lifelong gender dysphoria due to a gender assignment at birth that is in

76 ess-induced aversion, mitigated KOR-mediated dysphoria during acute and protracted withdrawal in opio

77 Increased symptoms of anxiety and dysphoria during opioid discontinuation are significant

78 fective symptoms reflecting areas of chronic dysphoria (e.g., anger and loneliness/emptiness) and int

79 eurological syndrome known as body integrity dysphoria express a desire to amputate seemingly healthy

80 h mania, and the bimodal distribution of the dysphoria factor is consistent with the possibility that

81 hypofunction and dysthymic disorder include dysphoria, fatigue, and low libido.

82 s-associated cluster significantly predicted dysphoria for 27 months after imaging controlling for pr

83 s, Tenth Revision diagnosis codes for gender dysphoria from the Veterans Health Administration nation

84 umber of people seeking treatment for gender dysphoria (GD) has risen in recent decades, yet data rem

85 Gender dysphoria (GD) is defined as a condition wherein a perso

86 Referrals for gender dysphoria (GD), characterized by a distressful incongrue

87 op surgery is associated with improved chest dysphoria, gender congruence, and body image satisfactio

88 dgeable about diagnostic criteria for gender dysphoria/gender incongruence, the use of medical and su

89 and loss (ie, emotional numbing, depression/dysphoria, generalized anxiety) symptomatology.

90 inverse of measures of pervasive anxiety and dysphoria (i.e., negative affectivity).

91 between autism spectrum disorder and gender dysphoria in 9 of 16 studies (56.3%), and a higher risk

92 olecular mechanisms mediating stress-induced dysphoria in humans and conditioned place aversion in ro

93 The first and strongest factor represented dysphoria in mania, with strong positive loadings for de

94 different forms of stress presumed to evoke dysphoria in mice, we found that repeated forced swim an

95 ms responsible for cognitive dysfunction and dysphoria in nondemented patients with Parkinson's disea

96 ductive age have some physical discomfort or dysphoria in the weeks before menstruation.

97 le in the assessment and treatment of gender dysphoria in transgender individuals.

98 enous puberty for patients with early gender dysphoria, in whom impending puberty is unacceptable for

99 eported more pain than those without current dysphoria, irrespective of whether they had a history of

100 Extreme dysphoria is common in borderline personality disorder (

101 Understanding how KOR activation produces dysphoria is key to the development of better analgesics

102 oid receptor (KOR) system leads to aversive, dysphoria-like behavior.

103 tors (KORs) in monoamine circuits results in dysphoria-like behaviors and stress-induced reinstatemen

104 ng in different stress responses: analgesia, dysphoria-like behaviors, anxiety-like responses, and in

105 ted and excitable mood states (mania) to the dysphoria, low energy, and despondency of depressive epi

106 This dysphoria may worsen as puberty progresses.

107 intervention group had a decrease in gender dysphoria (mean difference, -7.2 points; 95% CI, -8.3 to

108 The primary outcome was the Chest Dysphoria Measure (CDM).

109 roadly consistent with Simms and colleagues' Dysphoria Model of PTSD symptoms) which provided a bette

110 ed by neuroendocrine dysregulation, fatigue, dysphoria, myalgia, and impaired mental and physical per

111 e disorders, anhedonia (lack of pleasure) or dysphoria (negative affect) can result from breakdowns o

112 with lifetime anxiety disorders and lifetime dysphoria (odds ratio=3.82, 95% CI=1.56-9.38, and odds r

113 ia after quitting smoking and the effects of dysphoria on abstinence.

114 Among individuals with no history of dysphoria, only lithium use was significantly associated

115 clinically used KOR agonist, does not cause dysphoria or hallucinations at therapeutic doses in huma

116 been reported only among youths with gender dysphoria or in transgender individuals.

117 egulation of reward processing manifested in dysphoria, or affective withdrawal.

118 patial and mnemonic functioning but not with dysphoria; pattern 2 correlated with dysphoria but not w

119 itoral enlargement, and reductions in gender dysphoria, perceived stress, anxiety, and depression.

120 aused by treatments that cause anhedonia and dysphoria (prodepressive effects) in rats and humans (e.

121 essment forms and the Gender Identity/Gender Dysphoria Questionnaire for Adolescents and Adults, as r

122 ith general depression (R = -.523, P = .01), dysphoria (R = -.455, P = .05), and lassitude (R = -.449

123 e of these loci appear to be associated with dysphoria rather than with MDD, potentially decreasing t

124 and young adults with a diagnosis of gender dysphoria receiving health care through the US military

125 ny transgender adolescents experience gender dysphoria related to incongruence between their gender i

126 we discuss the evidence that drugs alleviate dysphoria related to lack of social connection or produc

127 The dependence of both negative (dysphoria-related) and positive (antidepressant-induced)

128 atment, indicating that these behaviors were dysphoria-related.

129 ssive symptoms at the time of the interview (dysphoria) reported more pain than those without current

130 tility, narcissism, emotional dysregulation, dysphoria, schizoid orientation, obsessionality, thought

131 or (KOR) activation contributes to aversion, dysphoria, sedation, depression, and enhanced psychostim

132 Some idioms for dysphoria seemed to work better than others.

133 epressed women met criteria for premenstrual dysphoria (symptom cyclicity and at least moderate sever

134 ms; this association was most pronounced for dysphoria symptoms (r = -0.45; 95% CI, -0.10 to -0.70).

135 ing and hyperarousal symptoms, and loss (ie, dysphoria) symptoms, such as emotional numbing and depre

136 typic expression of trauma-related loss (ie, dysphoria) symptoms.

137 ith episodes of binge cocaine use and in the dysphoria that follows abrupt cocaine withdrawal.

138 Compared with respondents with no history of dysphoria, the odds ratio for MI associated with a histo

139 : one defined by emotional dysregulation and dysphoria, the other by histrionic characteristics.

140 n-releasing factor (CRF) in the induction of dysphoria, the potentiation of drug seeking, and stress-

141 iated with the time from diagnosis of gender dysphoria to initiation of gender-affirming hormone ther

142 the time between initial diagnosis of gender dysphoria to the first prescription for gender-affirming

143 bic pathway has been proposed to mediate the dysphoria underlying this response, we tested dopamine-d

144 t symptoms within the same disorder (such as dysphoria vs. anxiety in patients with major depression)

145 ds ratio for MI associated with a history of dysphoria was 2.07 (95% CI, 1.16 to 3.71), and the odds

146 s-related symptom cyclicity nor premenstrual dysphoria was an invariant accompaniment of perimenopaus

147 Dysphoria was assessed at baseline and 2 years later.

148 Dysphoria was assessed at the time of imaging and prospe

149 In the entire group, dysphoria was found in 33%, delusional ideation in 39%,

150 Additionally, the rate of premenstrual dysphoria was not predicted by initial self-reports.

151 s-related symptom cyclicity and premenstrual dysphoria was observed in perimenopausal depressed women

152 Quality of life associated with gender dysphoria was substantially worse than that seen in youn

153 c correlates of responses to questions about dysphoria were examined.

154 al syndrome and postpartum or postmenopausal dysphoria, when increased emotional lability and BDZ ins

155 associated with traits that reflect general dysphoria, whereas the skip structure in the CIDI-SF all

156 ated female at birth (DFAB) experience chest dysphoria, which is associated with depression and anxie

157 ve emotional symptoms, such as anhedonia and dysphoria, which may be due in part, to dysfunction of t

158 hangeable; the former better indexes general dysphoria, while the latter is more informative about wi

159 tal of 75 participants diagnosed with gender dysphoria who had used puberty suppression before age 18

160 natal females meet DSM-5 criteria for gender dysphoria, with many of these individuals self-describin